Jan 09, 2023 / 06:30PM GMT
Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
Good morning, everyone. Welcome. My name is Jess Fye. I'm the large cap biotech analyst at JPMorgan, and we're delighted to be continuing the conference with BioMarin this morning. So good news, we're not going to switch rooms for Q&A today. There's going to be mic runners. If you have a question after the presentation, you can raise your hand, and someone will bring you a mic. You can also submit your questions electronically, and I can ask them.
So without further ado, let me pass it over to the company's CEO, JJ Bienaime.
Jean-Jacques Bienaime - BioMarin Pharmaceutical Inc. - Chairman & CEO
Thank you, Jess. Good morning, everybody. It's a pleasure to be back here in person after this COVID hiatus. As usual, this presentation will contain forward-looking statements. Please refer to our 10-K and 10-Q filings. So again, it's good to be back.
As you know, BioMarin is really anchored in science. And I would say all the genetic products
Biomarin Pharmaceutical Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers